Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b

Nobuyuki Matsumoto,Hiroki Ikeda,Ryuta Shigefuku,Nobuhiro Hattori,Tsunamasa Watanabe,Kotaro Matsunaga,Tetsuya Hiraishi,Tomohiro Tamura,Yohei Noguchi,Yasunobu Fukuda,Toshiya Ishii,Chiaki Okuse,Akira Sato,Michihiro Suzuki,Fumio Itoh

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b

2016

Nobuyuki Matsumoto
Hiroki Ikeda
Ryuta Shigefuku
Nobuhiro Hattori
Tsunamasa Watanabe
Kotaro Matsunaga
Tetsuya Hiraishi
Tomohiro Tamura
Yohei Noguchi
Yasunobu Fukuda
Toshiya Ishii
Chiaki Okuse
Akira Sato
Michihiro Suzuki
Fumio Itoh

Background Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).

Keywords:

NS5A
Hepatitis C virus
Hemoglobin
Hepacivirus
Virology
Asunaprevir
Daclatasvir
Combination therapy
NS3
Medicine
Virus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations